Antibody Profiling in COVID-19 Patients with Different
Severities by Using Spike Variant Protein Microarrays
Posted on 2022-04-20 - 16:08
The
disease progression of COVID-19 varies from mild to severe,
even death. However, the link between COVID-19 severities and humoral
immune specificities is not clear. Here, we developed a multiplexed
spike variant protein microarray (SVPM) and utilized it for quantifying
neutralizing activity, drug screening, and profiling humoral immunity.
First, we demonstrated the competition between antispike antibody
and ACE2 on SVPM for measuring the neutralizing activity against multiple
spike variants. Next, we collected the serums from healthy subjects
and COVID-19 patients with different severities and profile the neutralizing
activity as well as antibody isotypes. We identified the inhibition
of ACE2 binding was stronger against multiple variants in severe compared
to mild/moderate or critical patients. Moreover, the serum IgG against
nonstructural protein 3 was elevated in severe but not in mild/moderate
and critical cases. Finally, we evaluated two ACE2 inhibitors, Ramipril
and Perindopril, and found the dose-dependent inhibition of ACE2 binding
to all the spike variants except for B.1.617.3. Together, the SVPM
and the assay procedures provide a tool for profiling neutralizing
antibodies, antibody isotypes, and reagent specificities.
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Su, Wen-Yu; Du, Pin-Xian; Santos, Harvey M.; Ho, Tzong-Shiann; Keskin, Batuhan Birol; Pau, Chi Ho; et al. (2022). Antibody Profiling in COVID-19 Patients with Different
Severities by Using Spike Variant Protein Microarrays. ACS Publications. Collection. https://doi.org/10.1021/acs.analchem.1c05567
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (10)
WS
Wen-Yu Su
PD
Pin-Xian Du
HS
Harvey M. Santos
TH
Tzong-Shiann Ho
BK
Batuhan Birol Keskin
CP
Chi Ho Pau
AY
An-Ming Yang
YC
Yi-Yu Chou
HS
Hsi-Chang Shih
GS
Guan-Da Syu
KEYWORDS
assay procedures providespike variants exceptprofiling humoral immunityhumoral immune specificitiesprofiling neutralizing antibodiesquantifying neutralizing activitymultiple spike variantsnonstructural protein 3neutralizing activitymultiple variantsantibody profilingreagent specificitiesserum igghealthy subjectseven deathdrug screeningdisease progressiondifferent severitiescritical patientscritical casesantispike antibodyantibody isotypes19 varies19 severities19 patients